Dr. Wildon Farwell has over a decade of leadership experience in clinical development and medical affairs, with deep expertise in neuromuscular and rare diseases. He most recently served as chief medical officer and later as medical advisor at Dyne Therapeutics, where he established and led the development organization. At Dyne, he oversaw protocol design and regulatory strategy for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs and guided the execution of multiple potentially registrational clinical trials.

Prior to Dyne, Dr. Farwell spent ten years at Biogen, advancing through roles of increasing responsibility to become vice president of Late-Stage Clinical Development and global medical head of Neuromuscular Diseases. At Biogen, he led the development and lifecycle management of SPINRAZA®, the first FDA-approved treatment for spinal muscular atrophy, and initiated late-stage development of QALSODY®, an investigational therapy for amyotrophic lateral sclerosis (ALS). He also played a key role in biomarker strategy and pharmacovigilance across a range of therapeutic areas.

Before entering the biotechnology industry, Dr. Farwell was an assistant professor of Medicine at Harvard Medical School and practiced at both Brigham and Women’s Hospital and the VA Boston Healthcare System. He earned his medical degree from the University of Missouri School of Medicine and holds a Master of Public Health in Clinical Effectiveness from the Harvard T.H. Chan School of Public Health.